**Supplementary file 2.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Treated group** | **Number of Injected Cells** | **Route** | **Injection Volume** | **Number of Mice** |
| **Experiment**  **1** | Enriched CD8/NKG2D cells | 4X105 cells | i.d | 100 µl | 3 |
| PHA activated PBMCs | 4X105 cells | i.d | 100 µl | 3 |
| ILC1lc | 4X105 cells | i.d | 100 µl | 4 |
| **Experiment**  **2** | ILC1lc | 4X105 cells | i.d | 100 µl | 2 |
| ILC1lc + anti-CD3 Abs (OKT3, Miltenyi Biotech) | 4X105 cells | i.d | 100 µl | 2 |
| Enriched CD8/NKG2D cells | 4X105 cells | i.d | 100 µl | 2 |
| Enriched CD8/NKG2D cells + anti-CD3 Abs (OKT3, Miltenyi Biotech) | 4X105 cells | i.d | 100 µl | 2 |